Background
==========

Colorectal cancer (CRC) is the second commonest malignancy and has a five-year survival rate of approximately 50% \[[@B1],[@B2]\]. The majority of patients, particularly with early stage disease (Dukes\' A, Stage I), are treated with surgery \[[@B3]\]. For more advanced disease (Dukes\' C and D, Stage III or IV) surgery combined with adjuvant chemotherapy has proven survival benefits \[[@B4]-[@B6]\]. However, the disease outcome is very variable and prognosis and prediction of treatment response based on conventional disease staging criteria is not reliable \[[@B6],[@B7]\]. There has therefore been considerable interest in the development of more robust prognostic and predictive disease markers for patient stratification with the ultimate aim of tailoring treatment to the individual patient \[[@B8],[@B9]\].

Markers based on circulating carcinoembryonic antigen (CEA) levels and various tumour-associated gene mutations including microsatellite instability (MSI), loss of heterozygosity of 18q, deleted in colorectal cancer (DCC), mutations in *KRAS*, *BRAF*and *PIK3CA*genes have all been shown to be of some prognostic or predictive value (reviewed in \[[@B8],[@B10]\]). In particular, the mutational status of *KRAS*, *BRAF*and *PIK3CA*genes has recently been proposed as a reliable marker for predicting responders to new targeted agents for the epidermal growth factor receptor (EGFR) \[[@B11],[@B12]\]. In addition, gene expression profiling studies of both mRNA \[[@B13]\] and microRNA \[[@B14]\] have revealed tumour-associated gene expression signatures that form the basis for a molecular classification of disease sub-types that define disease course and treatment response (reviewed in \[[@B8]\]). These studies on gene mutations and RNA expression have been paralleled by analysis of the tumour cell proteome, most commonly employing the technique of two-dimensional difference gel electrophoresis (2D-DIGE) to identify proteins that are differentially expressed in tumour *verses*normal mucosa tissue (reviewed in \[[@B15]\]). An expanding list of candidate prognostic markers have emerged from these studies including for example, cathepsin D, S100A4 and APAF-1 \[[@B15]\].

As an alternative to 2D-DIGE, studies of other tumour types have also employed the technique of direct protein expression profiling of tumour/normal tissue by surface enhanced laser desorption ionisation time-of-flight mass spectrometry (SELDI-TOF) or by matrix-assisted laser desorption ionisation time of-flight-mass spectrometry (MALDI-TOF) mass spectrometry \[[@B16],[@B17]\]. This approach, which is most commonly associated with the development of serum-based diagnostic markers, offers a number of advantages over 2D-DIGE. Although the technique yields no information on the actual identities of proteins, the reproducible spectral profiles that are relatively simple to generate in high throughput studies allow robust classification models of different proteome populations to be built. For example, studies of lung \[[@B18]\], breast \[[@B19]\], head and neck cancer \[[@B20]\] have all shown that the spectral profiles of tumour and normal tissue can be accurately discriminated and in some cases sub-classified by direct protein profiling using SELDI/MALDI-TOF mass spectrometry. Only one previous study has reported on the detection of differences between normal mucosa, adenoma and colorectal carcinoma by using SELDI-TOF MS \[[@B21]\].

In the present study, we have evaluated the potential value of protein expression profiling of CRC tissue by MALDI-TOF mass spectrometry. In addition to comparing tumour with adjacent normal mucosa, we have investigated whether spectral profiles of tumour tissue can be used to classify various clinico-pathological features of disease. Since previous 2D-DIGE studies have reported abnormalities of protein expression profiles in tumour-adjacent normal tissue \[[@B22]\], we have also extended this analysis to normal mucosa tissue.

Methods
=======

Clinical specimens
------------------

Tissue samples were collected from a total of 36 patients with confirmed CRC at the time of surgical resection at Colchester General Hospital, Essex UK. All specimens were obtained following informed consent in accordance with local UK NHS Ethics Committee approval (protocol reference: MH 528). Surgically excised specimens were washed extensively in ice-cold 150 mM NaCl and samples of normal colonic mucosa (\>10 cm from tumour margin) and tumour tissues were excised using a scalpel and then snap frozen and transferred to a - 80°C freezer. The total time from surgical resection to snap freezing of specimens was \<30 mins.

Protein extraction and purification
-----------------------------------

Frozen tissue samples (approximately 250 mg) were ground using a mortar and pestle and then lysed for 30 mins at 4°C in 1.0 ml of 10 mM Tris-HCl pH 7.5, 200 mM NaCl containing Protease inhibitor cocktail (Roche Pharmaceuticals) and 1% N-octyl-β-D-glucopyranoside (Sigma Aldrich). The cell lysate was then centrifuged at 12,000 × g for 30 mins and the supernatant representing the solubilised fraction was removed. Protein was further purified by reversed phase hydrophobic interaction chromatography using a commercially available super-paramagnetic microparticle kit (MB-HIC-C8, Bruker Daltonics). Briefly, 10 μl of 30-35 mg/ml protein solution was adsorbed to 10 μl of beads after addition of 20 μl kit binding buffer. After three washes with 200 μl 0.1% trifluoroacetic acid, protein was eluted in 20 μl of 50% (v/v) acetonitrile (Fisher Scientific) Eluted protein was stored at 4°C for no more than 1 hr prior to matrix co-crystallisation.

MALDI-TOF mass spectrometry
---------------------------

To facilitate reproducible co-crystallisation of protein with matrix solution, a modification of the slow crystallisation method \[[@B23]\] was used. Briefly, 20 ul of purified protein was mixed with 20 μl of acetonitrile containing 0.1% trifluoroacetic acid, saturated with sinapic acid (Sigma Aldrich). A 20 μl aqueous solution containing diammonium citrate (200 mM) and nitrotetracetic acid (0.1%) was added and crystal formation was allowed to proceed for 2-3 hrs. Crystallised matrix-protein samples were spotted onto a stainless steel MALDI target plate and spectra were acquired using a MALDI-TOF mass spectrometer (Reflex IV; Bruker Daltonics) with the following instrument settings: ion source 1, 20 kV; ion source 2, 16.65 kV; lens voltage, 9.5 kV; pulsed ion extraction, 200 ns. Ionisation was achieved by irradiation with a nitrogen laser (e = 337 nm) operating at 25 Hz and 20% laser power. For matrix suppression, we used a high gating factor with signal suppression up to 1500 Da. Mass spectra were detected in linear positive mode. Detector gain was set at 1600 V, sample rate at 1.0 and electronic gain at 100 mV with real-time smoothing. Spectra were acquired in duplicate from 500 laser shots delivered as 5 × 100 pulses and were internally calibrated using \'FlexAnalysis\' spectral processing software (Version 2.0; Bruker Daltonics) with reference marker peaks at 2426.9Da, 6109.5 Da and 12471.6 Da. External calibration used the following reference standards: bombesin (1620.86 Da), somatostatin (3149.57 Da), insulin (5734.51 Da), ubiquitin I (8565.76 Da), cytochrome c (12,360.97 Da) and myoglobin (16,952.30 Da).

Spectral processing and analysis
--------------------------------

Calibrated spectra were exported as ASCII files and were digitally processed by smoothing, de-noising, baseline subtraction and normalisation (by total ion current) using the \'SpecAlign\' suite of spectral computational tools \[[@B24],[@B25]\]. Validation of the reproducibility of the resulting mass spectrometry profiles and elimination of \'outliers\' was accomplished as described elsewhere \[[@B26]\]. Duplicate spectra with a cross-correlation function of \< 0.950 were discarded. From the initial cohort of specimens, representing matched tumour and adjacent normal mucosa from 36 patients, a total of 64 spectra representing 31 tumours and 33 normal mucosa were obtained (see Table [1](#T1){ref-type="table"}). Of the 5 tumour and 3 mucosa specimens that were excluded from analysis, 2 tumour and one mucosa failed to yield reproducible spectra on repeated protein preparations. The remaining 3 tumour and 2 mucosa specimens consistently gave spectra of poor quality (outliers), presumably as a result of specimen deterioration. Matching peaks were aligned across spectra by using the combined Fast Fourier Transform/Peak matching method \[[@B25]\] and modelled peak areas for the entire set of spectra were exported as a single csv file.

###### 

Clinico-pathological features of patient specimens

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumour   ^1^NM    Age   Gender   Dukes\' stage   TNM stage            Differentiation   Vascular\   ^2^LNs harvested   LNs pos   Patient status          ^3^Follow-up time
                                                                                          invasion                                                         
  -------- -------- ----- -------- --------------- -------------------- ----------------- ----------- ------------------ --------- ----------------------- -------------------
  \-       001NM    78    F        B               pT3, pN0, pR0        Poor              Absent      15                 0         Well & symptom free     48

                                                                                                                                                           

  002T     002NM    91    M        B               pT3, pN0, pR0        Moderate          Absent      9                  0         Deceased (recurrence)   35

                                                                                                                                                           

  003T     003NM    75    M        C1              pT3, pN1, pR0        Poor              Absent      10                 3         Well & symptom free)    36

                                                                                                                                                           

  004T     004NM    74    F        C1              pT4, pN1, pR2        Poor              Present     11                 3         Deceased (recurrence)   \<1

                                                                                                                                                           

  005T     005NM    76    M        B               pT3, pN0, pR0        Poor              Absent      6                  0         Well & symptom free     49

                                                                                                                                                           

  \-       006NM    69    F        A               pT2, pN0, pR0        Well              Absent      11                 0         Well & symptom free     40

                                                                                                                                                           

  \-       007NM    52    M        C1              pT3, pN1, pR0        Poor              Absent      23                 3         Well & symptom free     48

                                                                                                                                                           

  008T     008NM    63    F        C1              pT4, pN0, pR0        Poor              Absent      10                 0         Deceased (recurrence)   40

                                                                                                                                                           

  009T     009NM    68    M        B               pT3, pN0, pR0        Poor              Absent      8                  8         Well & symptom free     36

                                                                                                                                                           

  011T     011NM    77    M        C1              pT4,p N1, pR0        Poor              Absent      15                 3         Well & symptom free     40

                                                                                                                                                           

  016T     016NM    61    M        C2              pT2, pN2, pR0        Moderate          Present     14                 5         Well & symptom free     43

                                                                                                                                                           

  017T     017NM    65    F        B               pT3, pN0, pR0        Moderate          Absent      14                 0         Well & symptom free     39

                                                                                                                                                           

  020T     020NM    65    F        B               pT3, pN0, pR0        Poor              Absent      12                 0         Well & symptom free     36

                                                                                                                                                           

  021T     021NM    72    M        B               pT4, pN1, pR0        Moderate          Present     5                  1         Well & symptom free     28

                                                                                                                                                           

  023T     023NM    59    M        B               pT3, pN0, pR0        Moderate          Absent      10                 0         Well & symptom free     20

                                                                                                                                                           

  024T     024NM    41    F        C2              pT4, pN1, pRx        Well              Absent      15                 2         Deceased (recurrence)   30

                                                                                                                                                           

  025T     \-       82    M        B               pT4, pN0, pMx, pRx   Poor              Absent      7                  0         Deceased (recurrence)   13

                                                                                                                                                           

  026T     026NM    76    F        A               pT2, pN0, pR0        Moderate          Absent      5                  0         Deceased (recurrence)   36

                                                                                                                                                           

  028T     028NM    86    F        C1              pT3, pN1, pR0        Moderate          Absent      12                 0         Well & symptom free     36

                                                                                                                                                           

  029T     029NM    71    F        B               pT3, pN0, pR0        Well              Absent      32                 0         Well & symptom free     36

                                                                                                                                                           

  031T     031NM    82    M        C2              pT3, pN2, pR0        Poor              Present     11                 3         Well & symptom free     36

                                                                                                                                                           

  032T     032NM    69    F        B               pT4, pN0, pR0        Moderate          Absent      11                 0         Well & symptom free     23

                                                                                                                                                           

  033T     033NM    72    M        C1              pT4, pN1, pR0        Moderate          Absent      8                  1         Well & symptom free     22

                                                                                                                                                           

  034T     034NM    58    M        C1              pT4, pN1, pR0        Moderate          Absent      5                  3         Well & symptom free     25

                                                                                                                                                           

  \-       035NM    77    F        B               pT3, pN0, pR0        Poor              Absent      7                  0         Well & symptom free     25

                                                                                                                                                           

  036T     \-       81    F        B               pT3, pN0, pR0        Moderate          Absent      13                 0         Well & symptom free     21

                                                                                                                                                           

  037T     037NM    77    F        B               pT3, pN0, pR0        Well              Absent      7                  0         Well & symptom free     19

                                                                                                                                                           

  038T     038NM    76    F        A               pT2, pN1, pR0        Poor              Absent      5                  1         Well & symptom free     20

                                                                                                                                                           

  039T     039NM    75    F        B               pT3, pN0, pR0        Moderate          Absent      16                 0         Well & symptom free     23

                                                                                                                                                           

  2012T    2012NM   62    M        C1              pT3, pN1, pR0        Poor              Present     18                 3         Well & symptom free     20

                                                                                                                                                           

  2018T    2018NM   83    F        A               pT1, pN0, pR0        Moderate          Absent      6                  0         Deceased (unrelated)    2

                                                                                                                                                           

  2022T    2022NM   56    M        B               pT3, pN0, pR0        Well              Present     20                 0         Well & symptom free     20

                                                                                                                                                           

  2044T    2044NM   82    M        A               pT2, pN0, pR0        Moderate          Absent      10                 0         Well & symptom free     21

                                                                                                                                                           

  \-       2080NM   72    F        A               pT2, pN0, pR0        Moderate          Absent      5                  0         Well & symptom free     21

                                                                                                                                                           

  2084T    \-       38    M        B               ypT3, ypN0, ypR0     Poor              Absent      10                 0         Well & symptom free     20

                                                                                                                                                           

  2085T    2085NM   78    F        C1              pT3, pN1, pR0        Moderate          Absent      11                 1         Deceased (unrelated)    \<1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^NM = normal mucosa; ^2^LN = lymph node; ^3^follow-up time in months

Subsequent spectral analysis was implemented in the \'GenePattern\' suite of software tools (Broad Institute, MIT, USA) \[[@B27]\]. Hierarchical clustering used Euclidean correlation as the column distance measure with pair-wise average linkage as the clustering method. Comparative Gene Marker Selection \[[@B28],[@B29]\] with either a t-test or a signal-to-noise ratio (SNR) test statistic was used to identify and rank differentially expressed marker peaks and to assign Bonferroni-corrected *P*and false discovery rate (FDR) values \[[@B28]-[@B30]\]. The *k*-nearest neighbours (*k*NN) algorithm \[[@B29]\] was used to build a classification model for tumour *vs*normal using separate training and test datasets. For this purpose, two thirds of the spectra, comprised of a representative proportion of tumour and normal spectra, were randomly assigned to a training dataset, with the remaining third being used as an independent test dataset. Spectra were randomly assigned using the GenePattern \'SplitDatasetTrainTest\' module \[[@B27]\]. Alternatively the *k*NN algorithm was used in an iterative, \'leave-one-out\' cross-validation mode. Other statistical analysis used the SPSS software.

Results
=======

Spectral profiles in tumour and normal mucosa tissues
-----------------------------------------------------

Table [1](#T1){ref-type="table"} summarises the clinico-pathological data for the 36 CRC patients from whom specimens were obtained. In most cases, spectra of adequate quality from matching pairs of tumour and adjacent normal mucosa were obtained. However, some tissue protein preparations consistently yielded spectra of poor quality or that were poorly reproducible (see Methods section); these were excluded from the analysis. The resulting 64 spectra, representing 31 tumour and 33 normal mucosa specimens, generated a total of 265 protein peaks in the mass range 1800-16000Da. Illustrative examples of raw MALDI-TOF spectral profiles are shown in additional file [1](#S1){ref-type="supplementary-material"}. Although the overall intensity profile of individual protein peaks was very heterogeneous across different specimens, unsupervised hierarchical cluster analysis classified most tumour and normal mucosa into distinct cluster groups (Figure [1](#F1){ref-type="fig"}) consistent with major differences in the tumour *verses*normal protein expression profiles.

![**Unsupervised hierarchical cluster analysis of tumour and normal mucosa spectra**. The dendrogram and heatmap show the clustering of Tumour (T) and normal mucosa (NM) spectra using Euclidean correlation as the column distance measure with pair-wise average linkage as the clustering method. Row clustering (not shown) used Spearman\'s rank correlation as distance measure with pair-wise complete linkage as the clustering method. Specimens are colour-coded as green (NM) and red (T).](1471-2407-10-410-1){#F1}

To quantitatively evaluate the differences between the protein expression profiles of tumour *verses*normal tissue, the Comparative Gene Marker Selection algorithm \[[@B28]\] was applied to the spectral data-set to determine the level of significance of difference between tumour and normal for each protein peak. Figure [2](#F2){ref-type="fig"} shows the frequency distribution (occurrences) of protein peak *P*values (Feature P) that were binned in increments of 0.05. Above *P*= 0.05, the representation of protein peaks was fairly evenly distributed. However, nearly 100 peaks gave a *P*value \< 0.05, indicating that a sizable fraction of proteins detected by MALDI-TOF mass spectrometry discriminate between tumour and normal colonic tissue. Applying a threshold of *P*≤ 0.01, FDR ≤ 0.05, the expression profile of a total of 73 protein peaks was significantly different between tumour and normal tissue with 57 being up-regulated in normal tissue and 16 being up-regulated in tumour tissue. Figure [3](#F3){ref-type="fig"} shows a heat-map profile of these \'marker peaks\' and additional file [2](#S2){ref-type="supplementary-material"} summarises their statistical features.

![**Probability distribution of marker peaks distinguishing tumour from normal mucosa**. Spectra from all 64 tumour and normal tissue samples were analysed by Comparative Gene Marker Selection \[[@B28]\] using the SNR test statistic to identify peaks (features) that discriminate tumour from normal tissue. The feature P histogram shows the number of peaks (occurrences) that fall within binned *P*values.](1471-2407-10-410-2){#F2}

![**Heat map profile of marker peaks discriminating tumour from normal mucosa**. The expression profiles and m/z values of the top 73 ranked peaks identified by Comparative Gene Marker Selection \[[@B28]\] (*P*= ≤ 0.01, FDR = ≤ 0.05) are depicted for all 64 tissue specimens.](1471-2407-10-410-3){#F3}

To rigorously demonstrate that tumour and normal mucosa tissue could be distinguished using their protein spectral profiles, the 64 spectra were randomly split into separate training and test datasets. The training spectra dataset was used to optimise a *k*NN algorithm \[[@B29]\] for predicting tumour or normal status. As summarised in additional file [3](#S3){ref-type="supplementary-material"}, the model correctly predicted the status of specimens in the independent test spectra dataset with 100% sensitivity and specificity (95% confidence interval: 67.9-99.2%).

Classification of clinico-pathological characteristics from tumour spectra
--------------------------------------------------------------------------

To determine whether the protein expression profiles of tumour tissue could be used to predict individual clinico-pathological characteristics of patients (Table [1](#T1){ref-type="table"}), the *k*NN algorithm was used to optimise a series of classification models. Since the limited numbers of datasets precluded analysis by using independent train and test spectra, the *k*NN algorithm was used in an iterative, \'leave-one-out\' cross-validation mode. Table [2](#T2){ref-type="table"} summarises the results of this analysis. The predictive model for distinguishing poorly differentiated from well/moderately differentiated tumours gave a receiver-operator characteristics (ROC) error of 0.171, correctly classifying 10/13 poorly differentiated and 16/18 well/moderately differentiated tumours (*P*= \< 0.001). Additional file [4](#S4){ref-type="supplementary-material"} summarises the *k*NN algorithm results and Figure [4A](#F4){ref-type="fig"} shows the expression profiles of the top two ranked discriminating peaks. The *k*NN model for disease recurrence also gave a low ROC error (0.105 - see Table [2A](#T2){ref-type="table"}). As summarised in additional file [5](#S5){ref-type="supplementary-material"}, the model correctly predicted 5/6 patients with recurrent disease and 22/23 who are disease-free (*P*= \< 0.001). Figure [4A](#F4){ref-type="fig"} shows the expression profiles of the top two ranked marker peaks for classifying disease outcome.

###### 

Performance of predictive models for classification of clinico-pathological characteristics in tumour tissue

  -------------------------------------------------------------------------------------------------------------------------------
  CHARACTERISTICS             ^1^Advanced Dukes\'\   Poorly differentiated   Lymph node\   Invasiveness   ^2^Disease recurrence
                              stage                                          involvement                  
  --------------------------- ---------------------- ----------------------- ------------- -------------- -----------------------
  Number of features          5                      2                       4             9              10

                                                                                                          

  Positive prediction rate    6/12                   10/13                   5/13          3/7            5/6

                                                                                                          

  Sensitivity                 0.500                  0.769                   0.385         0.429          0.833

                                                                                                          

  ^3^CI                       0.223-0.777            0.460-0.938             0.151-0.677   0.118-0.798    0.364-0.991

                                                                                                          

  Positive predictive value   0.750                  0.833                   0.625         0.750          0.833

                                                                                                          

  CI                          0.356-0.955            0.509-0.971             0.259-0.898   0.219-0.986    0.364-0.991

                                                                                                          

  Negative prediction rate    17/19                  16/18                   15/18         23/24          22/23

                                                                                                          

  Specificity                 0.894                  0.889                   0.833         0.958          0.957

                                                                                                          

  CI                          0.654-0.981            0.639-0.981             0.577-0.956   0.768-0.998    0.760-0.998

                                                                                                          

  Negative predictive value   0.739                  0.842                   0.652         0.852          0.957

                                                                                                          

  CI                          0.513-0.889            0.585-0.958             0.428-0.828   0.654-0.951    0.760-0.998

                                                                                                          

  Absolute error              0.258                  0.161                   0.355         0.161          0.069

                                                                                                          

  ^4^ROC error                0.302                  0.171                   0.391         0.307          0.105

                                                                                                          

  Fisher\'s exact test        *P*= 0.020             *P*= \< 0.001           *P*= 0.133    *P*= 0.027     *P*= \< 0.001
  -------------------------------------------------------------------------------------------------------------------------------

^1^Includes Dukes\' C1 and C2; ^2^Median follow-up time for recurrent disease patients: 33 months; median follow-up time for disease-free patient: 27 months (analysis excludes patients who died through surgical complications - see Table 1); ^3^CI = 95% confidence interval; ^4^ROC = receiver-operator characteristics

The KNN algorithm \[[@B29]\] was used in \'leave-one-out\' cross-validation prediction with the number of features (marker peaks) specified. Marker peaks were selected using a t-test statistic except for lymph node involvement and invasiveness characteristics of tumour tissue where the SNR test statistic was used.

![**Relative ion intensity profiles of marker peaks used in predictive algorithms of tumour/mucosa clinico-pathological features**. The peak intensity profiles of the top two-ranked scoring peaks are shown for tumour spectra (A) for classifying differentiation and disease recurrence and for normal mucosa spectra (B) for classifying lymph node involvement (see Table 2). The performance of predictive models for these clinico-pathological features are shown in additional file [4](#S4){ref-type="supplementary-material"} (differentiation), in additional file [5](#S5){ref-type="supplementary-material"} (disease recurrence) and in additional file [6](#S6){ref-type="supplementary-material"} (lymph node involvement). The t-test *P*value is given for each marker peak.](1471-2407-10-410-4){#F4}

Classification of clinico-pathological characteristics from normal mucosa spectra
---------------------------------------------------------------------------------

In a similar analysis of normal mucosa spectra (Table [3](#T3){ref-type="table"}), only the characteristic of lymph node involvement gave a low ROC error (0.212). As shown in Table [3](#T3){ref-type="table"} and in additional file [6](#S6){ref-type="supplementary-material"}, the *k*NN algorithm correctly predicted 11/14 patients with, and 15/19 patients without lymph node involvement (*P*= 0.001). Figure [4B](#F4){ref-type="fig"} shows the expression profiles of the top two ranked marker peaks for classifying the characteristic of lymph node involvement.

###### 

**Performance of predictive models for classification of clinico-pathological characteristics in normal mucosa tissue**.

  -------------------------------------------------------------------------------------------------------------------------------
  CHARACTERISTICS             ^1^Advanced Dukes\'\   Poorly differentiated   Lymph node\   Invasiveness   ^2^Disease recurrence
                              stage                                          involvement                  
  --------------------------- ---------------------- ----------------------- ------------- -------------- -----------------------
  Number of features          7                      5                       3             6              7

                                                                                                          

  Positive prediction rate    8/13                   8/14                    11/14         3/7            0/5

                                                                                                          

  Sensitivity                 0.615                  0.571                   0.786         0.429          0.000

                                                                                                          

  ^3^CI                       0.322-0.849            0.296-0.812             0.488-0.943   0.116-0.798    0.000-0.537

                                                                                                          

  Positive predictive value   0.500                  0.444                   0.733         0.500          0.000

                                                                                                          

  CI                          0.255-0.749            0.224-0.686             0.448-0.911   0.139-0.860    0.000-0.945

                                                                                                          

  Negative prediction rate    12/20                  9/19                    15/19         23/26          25/26

                                                                                                          

  Specificity                 0.600                  0.474                   0.789         0.885          0.962

                                                                                                          

  CI                          0.364-0.800            0.252-0.705             0.539-0.930   0.687-0.970    0.784-0.998

                                                                                                          

  Negative predictive value   0.706                  0.600                   0.833         0.852          0.833

                                                                                                          

  CI                          0.440-0.886            0.329-0.825             0.577-0.956   0.654-0.951    0.645-0.937

                                                                                                          

  Absolute error              0.394                  0.485                   0.212         0.212          0.194

                                                                                                          

  ^4^ROC error                0.392                  0.477                   0.212         0.343          0.519

                                                                                                          

  Fisher\'s exact test        *P*= 0.139             *P*= 0.267              *P*= 0.001    *P*= 0.082     *P*= 0.839
  -------------------------------------------------------------------------------------------------------------------------------

^1^Includes Dukes\' C1 and C2; ^2^Median follow-up time for recurrent disease patients: 33 months; median follow-up time for disease-free patient: 27 months (analysis excludes patients who died through surgical complications - see Table 1); ^3^CI = 95% confidence interval; ^4^ROC = receiver-operator characteristics

The KNN algorithm \[[@B29]\] was used in \'leave-one-out\' cross-validation prediction with the number of features (marker peaks) specified. Marker peaks were selected using a t-test statistic except for lymph node involvement and invasiveness characteristics of tumour tissue where the SNR test statistic was used.

Discussion
==========

Although previous studies employing 2D-DIGE analysis of CRC tissues have documented a number of proteins that are either up- or down-regulated in tumour *verses*normal mucosa \[[@B15]\], the extent to which protein expression profile differences can be detected by direct MALDI-TOF analysis in CRC was not previously known. Analysis of complex protein mixtures by MALDI-TOF MS is inherently limited by the resolution afforded by this type of instrument. Also, only a minor fraction of protein species are efficiently ionisable and therefore detectable. However, our results show that, in common with similar studies in some other solid tumour types \[[@B18]-[@B20]\], MALDI-TOF MS readily detects a sizable fraction of protein marker peaks whose expression level is significantly different between tumour and normal mucosa. By using an optimised *k*NN training model, the classification of tumour and normal tissue was correctly predicted with 100% sensitivity and specificity (95% confidence interval: 0.679-0.992) in an independent test dataset. This performance compares favourably with other studies, for example in head and neck squamous cell carcinoma, in which supervised prediction using SELDI-TOF spectral data correctly classified healthy mucosa and tumour tissue with an accuracy of 94.5% and 92.9% respectively \[[@B20]\].

In further evaluating the potential value of spectra generated from tumour tissue for classifying various clinic-pathological characteristics of disease, we observed low ROC errors with the *k*NN predictive models for differentiation (0.171) and disease recurrence (0.105). Since histological differentiation stage is a characteristic that is intrinsic to the tumour tissue (and would most closely reflect the actual tumour cell proteome), the ability of the spectra to discriminate well/moderately differentiated from poorly differentiated histologies is perhaps unsurprising. The good performance of the predictive model for disease recurrence is consistent with data from several microarray expression profiling studies that have clearly demonstrated associations between patterns of tumour-associated gene expression and prognosis/treatment response \[[@B8],[@B13],[@B14]\]. However, given that in our study, only six patients had succumbed to recurrent disease at the time of data analysis (median follow-up time for recurrent disease patients: 33 months; median follow-up time for disease-free patient: 27 months), our results should be interpreted with caution. It is also important to emphasise that because of the relatively small number of tumour specimens, rigorous validation of correlations with disease recurrence and histological differentiation stage in an independent \'test\' datsaset was not possible in our study.

Several lines of evidence indicate that the normal mucosa from surgically resected CRC tumour specimens display abnormalities in gene and protein expression. These abnormalities have been attributed to precancerous \'field effect\' changes in tumour-adjacent mucosa and have been reported to affect protein expression \[[@B22]\], CpG island gene methylation \[[@B31]\] and gene microarray expression profiles \[[@B32]\]. Indeed one study has reported that gene expression profiling of non-neoplastic mucosa may predict clinical outcome of CRC patients \[[@B32]\]. These findings are reminiscent of reports from studies of other solid tumour types, most strikingly in hepatocellular carcimoma in which gene expression patterns of non-neoplastic liver tissue were predictive of patient survival, whereas tumour tissue gene expression signatures were of no prognostic value \[[@B33]\]. It was therefore of interest in our study to determine whether the protein expression profiles of normal mucosa could be used to classify any clinico-patholgical characteristics. Although we found no evidence for predictive value for disease relapse (ROC error, 0.519), the *k*NN model of normal mucosa spectra for lymph node involvement did give a low ROC error (0.212); the corresponding *k*NN model for tumour spectra did not show predictive value (0.391). One plausible scenario to explain the predictive value of normal mucosa spectra for lymph node involvement is that paracrine/inflammatory mechanisms, involving proximal affected lymph nodes, may induce changes to the microenvironment of tumour-adjacent mucosa.

As an essential pre-requisite for marker validation, it would be highly desirable in future studies to determine the identities of candidate marker peaks in tumour tissue that discriminate different histological differentiation stages and predict disease recurrence. Our findings also indicate that similar studies using the alternative approach of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in CRC are warranted.

Conclusions
===========

In summary, our study has shown that direct protein expression profiling of surgically resected CRC tissue by MALDI-TOF mass spectrometry has potential value in studies aimed at improved molecular classification of this disease. Further studies, with longer follow-up times and larger patient cohorts, that would permit independent validation of predictive models, would be required to confirm the predictive value of tumour spectra for disease recurrence/patient survival.
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